SUBODH VERMA

BIOGRAPHY

A Passion for Science, Surgery, and Mentorship

Dr Subodh Verma, MD, PhD, FRCSC, FAHA, FCAHS, is an internationally recognized cardiac surgeon–scientist and Professor of Surgery at the University of Toronto. He holds the Canada Research Chair in Cardiovascular Surgery (formerly Atherosclerosis, 2007-17) and is a Fellow of the Canadian Academy of Health Sciences. His honours include Clarivate Highly Cited Researcher in Clinical Medicine (since 2022), the 2023 Cumming School of Medicine Alumnus of Distinction for Research, the 2021 University of Toronto Lister Prize, the Howard Morgan Award for Distinguished Achievements in Cardiovascular Research, and the Royal College of Physicians and Surgeons of Canada Gold Medal in Surgery. Dr Verma is an appointee of the American Association for Thoracic Surgery and a past member of the Royal Society of Canada College of New Scholars, Artists and Scientists.

As of May 2026, his ≈1000 peer-reviewed papers have yielded an h-index of 146 and >110,000 citations. They appear in leading key journals including NEJM, Lancet, Nature, Circulation, European Heart Journal and JACC. He is Editor-in-Chief of Current Opinion in Cardiology; Associate Editor of the Journal of Thoracic and Cardiovascular Surgery and European Journal of Heart Failure; and Editorial Consultant for JACC. Dr Verma contributes to Canadian and American practice guidelines on atrial fibrillation, antiplatelet therapy, cardiac surgery, cardiorenal protection, diabetes, heart failure and peripheral artery disease. He chairs the Scientific Program Committee of the Canadian Society of Cardiac Surgeons and has served the AHA Council on Cardiovascular Surgery and Anesthesia since 2008.

He holds or has recently held leadership roles in numerous global heart-failure, cardiometabolic and atherosclerosis trials that have reshaped clinical guidelines recommendations. To support surgical evidence, he founded CardioLink in 2015, uniting cardiac surgeons nationwide to perform practice-changing trials; CardioLink has since broadened to cardiometabolic studies and produced 40+ papers, with several trials presented as late-breakers at AHA and ESC.